SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-300661
Filing Date
2014-08-07
Accepted
2014-08-07 16:06:24
Documents
12
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d762817d10q.htm 10-Q 542209
2 EX-10.14 d762817dex1014.htm EX-10.14 26816
3 EX-31.1 d762817dex311.htm EX-31.1 9649
4 EX-31.2 d762817dex312.htm EX-31.2 9407
5 EX-32.1 d762817dex321.htm EX-32.1 5973
12 GRAPHIC g762817g49q79.jpg GRAPHIC 8218
  Complete submission text file 0001193125-14-300661.txt   3769227

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT aldx-20140630.xml EX-101.INS 432704
7 XBRL TAXONOMY EXTENSION SCHEMA aldx-20140630.xsd EX-101.SCH 41613
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aldx-20140630_cal.xml EX-101.CAL 40719
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aldx-20140630_def.xml EX-101.DEF 164830
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20140630_lab.xml EX-101.LAB 325942
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20140630_pre.xml EX-101.PRE 235393
Mailing Address 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803
Business Address 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803 617-513-9882
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 141023873
SIC: 2834 Pharmaceutical Preparations